Your session is about to expire
← Back to Search
Carfilzomib-based Chemotherapy for Multiple Myeloma (CarMob Trial)
CarMob Trial Summary
This trial is testing a new cancer drug, Carfilzomib, given with other drugs, to see what dose is safe for people.
CarMob Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCarMob Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 126 Patients • NCT03029234CarMob Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You need to have had a heart scan showing that your heart is pumping well within the last 6 months.I have not had radiation therapy in the last 3 weeks.Participants must have detectable levels of specific proteins in their blood or urine that can be measured.I do not have any uncontrolled illnesses like high blood pressure, diabetes, infections, or liver disease.I have multiple myeloma with measurable indicators.I finished my initial cancer treatment but didn't achieve total remission.Your body has enough white blood cells to fight off infections. If you have bone marrow biopsy showing a lot of myeloma, a lower count is okay.Your platelet count is at least 50,000 per cubic millimeter (or at least 30,000 for patients with a lot of myeloma in their bone marrow).I am 18 years old or older.I can do all or most of my daily activities without help.I have undergone stem cell transplant or preparation for it.I have moderate to severe nerve damage in my hands or feet.Your liver enzyme levels are not more than three times the normal limit.Your liver test results should show a certain level of a specific enzyme called SGPT/ALT.I haven't had cancer, except for certain skin cancers or low-risk prostate cancer treated fully, in the last 3 years.I agree to use two effective birth control methods if I'm sexually active.I agree not to donate sperm during and for 3 months after my carfilzomib treatment.I do not have any active infections or health issues that would make this treatment too risky for me.Your hemoglobin level is higher than 9.0 grams per deciliter.I have active HIV or active hepatitis A, B, or C.My high blood pressure is not under control.I have high blood pressure in the lungs.The level of bilirubin in your blood should be less than 1.5 times the upper limit of normal.If you are a woman who could become pregnant, you need to have a negative pregnancy test within a week before starting treatment and another negative test within 24 hours before taking the study drug.I do not have severe heart disease or recent heart attacks.
- Group 1: Carfilzomib Mobilization - Dose Level 5
- Group 2: Carfilzomib Mobilization - Dose Level 4
- Group 3: Carfilzomib Mobilization - Dose Level 0
- Group 4: Carfilzomib Mobilization - Dose Level 1
- Group 5: Carfilzomib Mobilization - Dose Level 2
- Group 6: Carfilzomib Mobilization - Dose Level 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any records of prior investigations involving Carfilzomib?
"Currently, 1367 trials for Carfilzomib are in progress with 288 taking place at the advanced Phase 3 level. While most of those studies originate from Philadelphia, Pennsylvania there is a total of 432 locations around the world conducting research on this drug."
Are new participants able to join this medical trial at this time?
"Details on clinicaltrials.gov demonstrate that this investigation is looking for contributors at present. It was initially published on October 8th 2019 and the most recent update took place August 5th 2022."
What is the maximum capacity of participants in this clinical experiment?
"Affirmative. Clinicaltrials.gov has information indicating that recruitment for this research project is ongoing, as evidenced by its initial post date of October 8th 2019 and last update on August 5th 2022. 18 participants are being sought from a single location."
Has Carfilzomib been sanctioned by the FDA?
"Carfilzomib's safety is assessed with a score of 1, as this phase one trial has limited clinical data to support its efficacy and security."
What health issues does Carfilzomib typically address?
"Carfilzomib is used to mitigate the effects of synovitis, ophthalmia, sympathetic disorders, and lung cancers."
Share this study with friends
Copy Link
Messenger